Rubio-Briones, Jose; Guerrero Ramos, Felix; Mercade Sanchez, Asier; Bezana Abadia, Ines; Rodriguez, Ruth Martin; Alcaraz, Antonio; Miqueleiz Legaz, Maite; Lozano, Fernando; Arrabal Martin, Miguel; Luis Cardo, Adrian; Gonzalo Rodriguez, Victoria; Cano Velasco, Jorge; Serrano Liesa, Miriam; Ferreiro Pareja, Cristina; Espilez Ortiz, Raquel; de Gonzalez-Valcarcel de Torres, Ignacio; Sanchez Zalabardo, Daniel; Esquinas, Cristina; Mengual, Lourdes; Borque-Fernando, Angel; Esteban Escano, Luis Mariano; Palou Redorta, Joan; Witjes, Fred; Martinez Pineiro, Luis

Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey

指导晚期尿路上皮癌一线治疗决策：一项全球调查

ONCOLOGIST

IF4.2

2025-10-010

OAAI

Grande, Enrique; Bellmunt, Joaquim; Hussain, Syed A.; Al Mansour, Mubarak M.; Bamias, Aristotle; Barthelemy, Philippe; Benjamin, David J.; Blais, Normand; Bourlon, Maria T.; Castellano, Daniel; Danchaivijitr, Pongwut; Fernandez Lazzaro, Mauricio; Giannatempo, Patrizia; Guerrero-Ramos, Felix; Iacovelli, Roberto; Ivanyi, Philipp; Jung, Eun Hee; Kanesvaran, Ravindran; Manneh, Ray; Marinho, Joana C.; Matsubara, Nobuaki; Merseburger, Axel S.; Mukherji, Deborah; Park, Chandler H.; Tran, Ben; da Trindade, Karine Martins; Urun, Yuksel; Kamat, Ashish M.; Birtle, Alison J.

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

定义接受BCG免疫疗法治疗的T1高分级非肌层浸润性膀胱癌患者的统计学治愈

BJU International

IF4.4

2025-08-290

PRE

José Daniel Subiela; Irene de la Parra; Javier Taborda; Alberto Artiles Medina; Renate Pichler; Wojciech Krajewski; Cesar Mínguez Ojeda; Ana Fernández Mardomingo; Pedro Del Olmo Durán; Enrique López Pérez; Daniel A. González-Padilla; Júlia Aumatell; Keiichiro Mori; Pietro Scilipoti; Mattia Longoni; Mario de Angelis; Jorge Caño-Velasco; Alfonso Lafuente Puentedura; Lucia Polanco Pujol; Roberto Contieri; Andrea Gallioli; Andrzej Tukiendorf; David D'Andrea; Jeremy Yuen-Chun Teoh; Luca Afferi; Francesco Del Giudice; Gautier Marcq; Simone Albisinni; Francesco Soria; Laura S Mertens; Ekaterina Laukhtina; Karl Tully; Andrea Mari; Félix Guerrero-Ramos; Mario Alvarez-Maestro; Carlos Casanova Martín; Franklin Anagua Melendres; Oscar Buisan; José Agustín López-González; José Luis Dominguez-Escrig; Javier Aranda; José Luis Rodríguez Elena; Giuseppe Basile; Victoria Gómez Dos Santos; Marco Moschini; Benjamin Pradere; Eduardo Albers Acosta; Fernando Lozano Palacio; Albert Carrión Puig; Pablo Gajate; Ana Saiz; Paolo Gontero; Francisco Javier Burgos Revilla; From Young Academic Urologist: Urothelial Carcinoma Working Group

TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

TAR-200联合西特雷利单抗与西特雷利单抗单药治疗作为不适合或拒绝新辅助顺铂为基础化疗的肌层浸润性膀胱癌患者的新辅助治疗（SunRISe-4）：一项随机、开放标签Ⅱ期试验的期中分析

lancet oncology

IF0

2025-08-270

PRE

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

作者更正: Sasanlimab加BCG在BCG幼稚，高危非肌层浸润性膀胱癌中的应用: 随机3期CREST试验

Nature Medicine

IF50

2025-07-210